128 related articles for article (PubMed ID: 11022009)
1. Functional features of hepatitis C virus glycoproteins for pseudotype virus entry into mammalian cells.
Meyer K; Basu A; Ray R
Virology; 2000 Oct; 276(1):214-26. PubMed ID: 11022009
[TBL] [Abstract][Full Text] [Related]
2. Characterization of pseudotype VSV possessing HCV envelope proteins.
Matsuura Y; Tani H; Suzuki K; Kimura-Someya T; Suzuki R; Aizaki H; Ishii K; Moriishi K; Robison CS; Whitt MA; Miyamura T
Virology; 2001 Aug; 286(2):263-75. PubMed ID: 11485395
[TBL] [Abstract][Full Text] [Related]
3. Influence of N-linked glycans on intracellular transport of hepatitis C virus E1 chimeric glycoprotein and its role in pseudotype virus infectivity.
Beyene A; Basu A; Meyer K; Ray R
Virology; 2004 Jul; 324(2):273-85. PubMed ID: 15207615
[TBL] [Abstract][Full Text] [Related]
4. Coexpression of hepatitis C virus E1 and E2 chimeric envelope glycoproteins displays separable ligand sensitivity and increases pseudotype infectious titer.
Meyer K; Beyene A; Bowlin TL; Basu A; Ray R
J Virol; 2004 Dec; 78(23):12838-47. PubMed ID: 15542636
[TBL] [Abstract][Full Text] [Related]
5. Pseudotype hepatitis C virus enters immature myeloid dendritic cells through the interaction with lectin.
Kaimori A; Kanto T; Kwang Limn C; Komoda Y; Oki C; Inoue M; Miyatake H; Itose I; Sakakibara M; Yakushijin T; Takehara T; Matsuura Y; Hayashi N
Virology; 2004 Jun; 324(1):74-83. PubMed ID: 15183055
[TBL] [Abstract][Full Text] [Related]
6. Functional role of hepatitis C virus chimeric glycoproteins in the infectivity of pseudotyped virus.
Lagging LM; Meyer K; Owens RJ; Ray R
J Virol; 1998 May; 72(5):3539-46. PubMed ID: 9557633
[TBL] [Abstract][Full Text] [Related]
7. Characterization of host-range and cell entry properties of the major genotypes and subtypes of hepatitis C virus.
Lavillette D; Tarr AW; Voisset C; Donot P; Bartosch B; Bain C; Patel AH; Dubuisson J; Ball JK; Cosset FL
Hepatology; 2005 Feb; 41(2):265-74. PubMed ID: 15660396
[TBL] [Abstract][Full Text] [Related]
8. Hepatitis C virus E1 envelope glycoprotein interacts with apolipoproteins in facilitating entry into hepatocytes.
Mazumdar B; Banerjee A; Meyer K; Ray R
Hepatology; 2011 Oct; 54(4):1149-56. PubMed ID: 21735466
[TBL] [Abstract][Full Text] [Related]
9. Attenuation of recombinant vesicular stomatitis viruses encoding mutant glycoproteins demonstrate a critical role for maintaining a high pH threshold for membrane fusion in viral fitness.
Fredericksen BL; Whitt MA
Virology; 1998 Jan; 240(2):349-58. PubMed ID: 9454708
[TBL] [Abstract][Full Text] [Related]
10. Hepatitis C virus envelope glycoproteins and potential for vaccine development.
Beyene A; Basu A; Meyer K; Ray R
Vox Sang; 2002 Aug; 83 Suppl 1():27-32. PubMed ID: 12617098
[TBL] [Abstract][Full Text] [Related]
11. In vitro interaction between hepatitis C virus (HCV) envelope glycoprotein E2 and serum lipoproteins (LPs) results in enhanced cellular binding of both HCV E2 and LPs.
Wunschmann S; Muller HM; Stipp CS; Hemler ME; Stapleton JT
J Infect Dis; 2006 Oct; 194(8):1058-67. PubMed ID: 16991080
[TBL] [Abstract][Full Text] [Related]
12. Cross-reactive pseudovirus-neutralizing anti-envelope antibodies coexist with antibodies devoid of such activity in persistent hepatitis C virus infection.
Burioni R; Mancini N; Carletti S; Perotti M; Grieco A; Canducci F; Varaldo PE; Clementi M
Virology; 2004 Oct; 327(2):242-8. PubMed ID: 15351212
[TBL] [Abstract][Full Text] [Related]
13. Hepatitis C virus envelope protein E2 binds to CD81 of tamarins.
Allander T; Forns X; Emerson SU; Purcell RH; Bukh J
Virology; 2000 Nov; 277(2):358-67. PubMed ID: 11080483
[TBL] [Abstract][Full Text] [Related]
14. The hypervariable region 1 of the E2 glycoprotein of hepatitis C virus binds to glycosaminoglycans, but this binding does not lead to infection in a pseudotype system.
Basu A; Beyene A; Meyer K; Ray R
J Virol; 2004 May; 78(9):4478-86. PubMed ID: 15078928
[TBL] [Abstract][Full Text] [Related]
15. Sulfated homologues of heparin inhibit hepatitis C virus entry into mammalian cells.
Basu A; Kanda T; Beyene A; Saito K; Meyer K; Ray R
J Virol; 2007 Apr; 81(8):3933-41. PubMed ID: 17287282
[TBL] [Abstract][Full Text] [Related]
16. Complement-mediated enhancement of antibody function for neutralization of pseudotype virus containing hepatitis C virus E2 chimeric glycoprotein.
Meyer K; Basu A; Przysiecki CT; Lagging LM; Di Bisceglie AM; Conley AJ; Ray R
J Virol; 2002 Mar; 76(5):2150-8. PubMed ID: 11836392
[TBL] [Abstract][Full Text] [Related]
17. Cell entry of hepatitis C virus requires a set of co-receptors that include the CD81 tetraspanin and the SR-B1 scavenger receptor.
Bartosch B; Vitelli A; Granier C; Goujon C; Dubuisson J; Pascale S; Scarselli E; Cortese R; Nicosia A; Cosset FL
J Biol Chem; 2003 Oct; 278(43):41624-30. PubMed ID: 12913001
[TBL] [Abstract][Full Text] [Related]
18. Characterization of Glycoprotein-Mediated Entry of Severe Fever with Thrombocytopenia Syndrome Virus.
Tani H; Shimojima M; Fukushi S; Yoshikawa T; Fukuma A; Taniguchi S; Morikawa S; Saijo M
J Virol; 2016 Jun; 90(11):5292-5301. PubMed ID: 26984731
[TBL] [Abstract][Full Text] [Related]
19. Characterisation of the differences between hepatitis C virus genotype 3 and 1 glycoproteins.
Shaw ML; McLauchlan J; Mills PR; Patel AH; McCruden EA
J Med Virol; 2003 Jul; 70(3):361-72. PubMed ID: 12766998
[TBL] [Abstract][Full Text] [Related]
20. 293 cells over-expressing human ADI1 and CD81 are permissive for serum-derived hepatitis C virus infection.
Cheng JC; Yeh YJ; Pai LM; Chang ML; Yeh CT
J Med Virol; 2009 Sep; 81(9):1560-8. PubMed ID: 19626614
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
